

# **Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027**

<https://marketpublishers.com/r/G510E2AE4EC5EN.html>

Date: October 2022

Pages: 113

Price: US\$ 4,900.00 (Single User License)

ID: G510E2AE4EC5EN

## **Abstracts**

Global liquid biopsy market was valued at USD 2,728.57 million in 2021, and during the forecast period, it is expected to expand at a CAGR of 13.77%. An alternate way of detecting and diagnosing cancer is liquid biopsy. The primary reason propelling the growth of the liquid biopsy market is the rising incidence of cancer worldwide. Liquid biopsies aid in the early detection of cancer while traditional biopsy techniques do not allow the detection of cancer in the aged population.

Due to factors such as the rising prevalence of cancer, increased funding for research

to find new biomarkers, and increased emphasis on the use of liquid biopsy, the market is anticipated to experience rapid expansion.

The rise of the industry is partly a result of substantial investments made by biotechnology firms in the research and development of liquid biopsies. A further factor driving the growth of the liquid biopsy market in the years to come is the increasing use of liquid biopsy among prominent end users.

### Rising Incidence of Cancer

Several factors, including tobacco use, alcohol use, poor food, physical inactivity, and air pollution, are contributing to the rise in cancer cases in the modern world. The global incidence of cancer is rising, making it the second biggest cause of death. Breast cancer is now the most prevalent type of cancer diagnosed worldwide due to the increased prevalence of the disease among females.

### Growing adoption of Liquid Biopsy among major end users

As prospective screening, diagnostic, prognostic, and predictive tests in cancer, liquid biopsies have gained a lot of interest. Clinical oncology has undergone a significant revolution owing to liquid biopsy, which makes it easier to sample tumors, provide continuous monitoring through repeated sampling, enable the creation of specific treatment plans, and test for therapeutic resistance. Since most cancers are in contact with blood, liquid biopsy mostly includes blood collection, though mucosa, pleural effusions, urine, and cerebrospinal fluid (CSF) are also examined during the procedure. As a result, Liquid Biopsy offers improved diagnosis sensitivity and simplicity of recurring sampling throughout therapy in a far more practical and non-invasive manner.

### Increased Awareness Regarding Cancer

Today's population is more aware of the signs and symptoms of cancer, and they try to have their illness diagnosed when it is still in its early stages. As a result of early cancer detection, tumor progression monitoring, and clinical prognosis assessment capabilities, liquid biopsy technology is experiencing market expansion.

### Market Segmentation

The Global Liquid Biopsy Market is segmented based on Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, and Region. Based on

Offering, the market can be split into Testing Service, Kits, Platform, Other Consumables. Based on Technology, the market can be divided into Next Generation Sequencing, Polymerase Chain Reactions, Others. Based on Workflow, the market is divided into Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management. Based on Sample, the market is divided into Blood, Urine, Saliva, Others.

Based on Circulating Biomarker, the market is divided into Circulating Tumor Cells (CTCs), Cell Free RNAs, Exosomes & Extracellular Vesicles, Others. In terms of Application, the market can be categorized into Oncological v/s non-Oncological. Based on End User, the market is split into Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes.

### Company Profiles

F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., LungLife AI, Inc., Illumina, Inc., QIAGEN NV, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., Guardant Health Inc., Natera, Inc., Sysmex Corporation, Abcodia Ltd., Dxcover Limited are among some of the major market players in the Global Liquid Biopsy Market.

### Report Scope:

In this report, Global Liquid Biopsy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

#### Liquid Biopsy Market, By Offering:

Testing Service

Kits

Platform

Other consumables

#### Liquid Biopsy Market, By Technology:

Polymerase Chain Reaction

Next Generation Sequencing

Others

Liquid Biopsy Market, By Workflow:

Sample Preparation

Library Preparation

Sequencing

Data Analysis & Management

Liquid Biopsy Market, By Sample:

Blood

Urine

Saliva

Others

Liquid Biopsy Market, By Circulating Biomarkers:

Circulating Tumor Cells (CTCs)

Cell-free Nucleic Acids

Exosomes & Extracellular Vesicles

Others

Liquid Biopsy Market, By Application:

Oncological

Non- Oncological

## Liquid Biopsy Market, By Region:

### North America

United States

Canada

Mexico

### Europe

Germany

France

United Kingdom

Italy

Spain

Netherlands

Belgium

Denmark

### Asia-Pacific

China

India

Japan

South Korea

Australia

New Zealand

South America

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Egypt

Saudi Arabia

South Africa

UAE

Competitive Landscape:

Company Profiles: Detailed analysis of the major companies present in Global Liquid Biopsy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).



## Contents

### 1. PRODUCT OVERVIEW

### 2. RESEARCH METHODOLOGY

### 3. EXECUTIVE SUMMARY

### 4. IMPACT OF COVID-19 ON GLOBAL LIQUID BIOPSY MARKET

### 5. VOICE OF CUSTOMER

- 5.1. Cancer Prevalence, By Gender
- 5.2. Cancer Prevalence, By Age Group
- 5.3. Cancer Prevalence, By Region
- 5.4. Common Methods Used for Cancer Detection
- 5.5. Benefits of Using Liquid Biopsy
- 5.6. Barriers to Adoption of Liquid Biopsy

### 6. CLINICAL TRIAL ANALYSIS

### 7. PATENT ANALYSIS

### 8. GLOBAL LIQUID BIOPSY MARKET OUTLOOK

#### 8.1. Market Size & Forecast

##### 8.1.1. By Value

#### 8.2. Market Share & Forecast

##### 8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)

##### 8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)

##### 8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

##### 8.2.4. By Sample (Blood, Urine, Saliva, Others)

##### 8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

##### 8.2.6. By Application (Oncological v/s non-Oncological)

##### 8.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)



8.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

8.2.8. By Company (2021)

8.2.9. By Region

8.3. Market Map

## **9. NORTH AMERICA LIQUID BIOPSY MARKET OUTLOOK**

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)

9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)

9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

9.2.4. By Sample (Blood, Urine, Saliva, Others)

9.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

9.2.6. By Application (Oncological v/s non-Oncological)

9.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)

9.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

9.2.8. By Country

9.3. North America: Country Analysis

9.3.1. United States Liquid Biopsy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Offering

9.3.1.2.2. By Technology

9.3.1.2.3. By Workflow

9.3.1.2.4. By Sample

9.3.1.2.5. By Circulating Biomarker

- 9.3.1.2.6. By Application
- 9.3.1.2.7. By End User
- 9.3.2. Canada Liquid Biopsy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Offering
    - 9.3.2.2.2. By Technology
    - 9.3.2.2.3. By Workflow
    - 9.3.2.2.4. By Sample
    - 9.3.2.2.5. By Circulating Biomarker
    - 9.3.2.2.6. By Application
    - 9.3.2.2.7. By End User
- 9.3.3. Mexico Liquid Biopsy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Offering
    - 9.3.3.2.2. By Technology
    - 9.3.3.2.3. By Workflow
    - 9.3.3.2.4. By Sample
    - 9.3.3.2.5. By Circulating Biomarker
    - 9.3.3.2.6. By Application
    - 9.3.3.2.7. By End User

## **10. EUROPE LIQUID BIOPSY MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
  - 10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
  - 10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
  - 10.2.4. By Sample (Blood, Urine, Saliva, Others)
  - 10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
  - 10.2.6. By Application (Oncological v/s non-Oncological)

10.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)

10.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

10.2.7. By End User (Academic & Research Institutes, Clinical Laboratories, , Pharmaceutical & Biotechnology Companies)

10.2.8. By Country

10.3. Europe: Country Analysis

10.3.1. Germany Liquid Biopsy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Offering

10.3.1.2.2. By Technology

10.3.1.2.3. By Workflow

10.3.1.2.4. By Sample

10.3.1.2.5. By Circulating Biomarker

10.3.1.2.6. By Application

10.3.1.2.7. By End User

10.3.2. France Liquid Biopsy Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Offering

10.3.2.2.2. By Technology

10.3.2.2.3. By Workflow

10.3.2.2.4. By Sample

10.3.2.2.5. By Circulating Biomarker

10.3.2.2.6. By Application

10.3.2.2.7. By End User

10.3.3. United Kingdom Liquid Biopsy Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Offering

10.3.3.2.2. By Technology

10.3.3.2.3. By Workflow

10.3.3.2.4. By Sample

10.3.3.2.5. By Circulating Biomarker

- 10.3.3.2.6. By Application
- 10.3.3.2.7. By End User
- 10.3.4. Italy Liquid Biopsy Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Offering
    - 10.3.4.2.2. By Technology
    - 10.3.4.2.3. By Workflow
    - 10.3.4.2.4. By Sample
    - 10.3.4.2.5. By Circulating Biomarker
    - 10.3.4.2.6. By Application
    - 10.3.4.2.7. By End User
- 10.3.5. Spain Liquid Biopsy Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Offering
    - 10.3.5.2.2. By Technology
    - 10.3.5.2.3. By Workflow
    - 10.3.5.2.4. By Sample
    - 10.3.5.2.5. By Circulating Biomarker
    - 10.3.5.2.6. By Application
    - 10.3.5.2.7. By End User
- 10.3.6. Netherlands Liquid Biopsy Market Outlook
  - 10.3.6.1. Market Size & Forecast
    - 10.3.6.1.1. By Value
  - 10.3.6.2. Market Share & Forecast
    - 10.3.6.2.1. By Offering
    - 10.3.6.2.2. By Technology
    - 10.3.6.2.3. By Workflow
    - 10.3.6.2.4. By Sample
    - 10.3.6.2.5. By Circulating Biomarker
    - 10.3.6.2.6. By Application
    - 10.3.6.2.7. By End User
- 10.3.7. Belgium Liquid Biopsy Market Outlook
  - 10.3.7.1. Market Size & Forecast
    - 10.3.7.1.1. By Value
  - 10.3.7.2. Market Share & Forecast

- 10.3.7.2.1. By Offering
- 10.3.7.2.2. By Technology
- 10.3.7.2.3. By Workflow
- 10.3.7.2.4. By Sample
- 10.3.7.2.5. By Circulating Biomarker
- 10.3.7.2.6. By Application
- 10.3.7.2.7. By End User
- 10.3.8. Denmark Liquid Biopsy Market Outlook
  - 10.3.8.1. Market Size & Forecast
    - 10.3.8.1.1. By Value
  - 10.3.8.2. Market Share & Forecast
    - 10.3.8.2.1. By Offering
    - 10.3.8.2.2. By Technology
    - 10.3.8.2.3. By Workflow
    - 10.3.8.2.4. By Sample
    - 10.3.8.2.5. By Circulating Biomarker
    - 10.3.8.2.6. By Application
    - 10.3.8.2.7. By End User

## **11. ASIA-PACIFIC LIQUID BIOPSY MARKET OUTLOOK**

- 11.1. Market Size & Forecast
  - 11.1.1. By Value
- 11.2. Market Share & Forecast
  - 11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
  - 11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
  - 11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
  - 11.2.4. By Sample (Blood, Urine, Saliva, Others)
  - 11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
  - 11.2.6. By Application (Oncological v/s non-Oncological)
    - 11.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
    - 11.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
  - 11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

- 11.2.8. By Country
- 11.3. Asia-Pacific: Country Analysis
  - 11.3.1. China Liquid Biopsy Market Outlook
    - 11.3.1.1. Market Size & Forecast
      - 11.3.1.1.1. By Value
    - 11.3.1.2. Market Share & Forecast
      - 11.3.1.2.1. By Offering
      - 11.3.1.2.2. By Technology
      - 11.3.1.2.3. By Workflow
      - 11.3.1.2.4. By Sample
      - 11.3.1.2.5. By Circulating Biomarker
      - 11.3.1.2.6. By Application
      - 11.3.1.2.7. By End User
  - 11.3.2. India Liquid Biopsy Market Outlook
    - 11.3.2.1. Market Size & Forecast
      - 11.3.2.1.1. By Value
    - 11.3.2.2. Market Share & Forecast
      - 11.3.2.2.1. By Offering
      - 11.3.2.2.2. By Technology
      - 11.3.2.2.3. By Workflow
      - 11.3.2.2.4. By Sample
      - 11.3.2.2.5. By Circulating Biomarker
      - 11.3.2.2.6. By Application
      - 11.3.2.2.7. By End User
  - 11.3.3. Japan Liquid Biopsy Market Outlook
    - 11.3.3.1. Market Size & Forecast
      - 11.3.3.1.1. By Value
    - 11.3.3.2. Market Share & Forecast
      - 11.3.3.2.1. By Offering
      - 11.3.3.2.2. By Technology
      - 11.3.3.2.3. By Workflow
      - 11.3.3.2.4. By Sample
      - 11.3.3.2.5. By Circulating Biomarker
      - 11.3.3.2.6. By Application
      - 11.3.3.2.7. By End User
  - 11.3.4. South Korea Liquid Biopsy Market Outlook
    - 11.3.4.1. Market Size & Forecast
      - 11.3.4.1.1. By Value
    - 11.3.4.2. Market Share & Forecast

- 11.3.4.2.1. By Offering
- 11.3.4.2.2. By Technology
- 11.3.4.2.3. By Workflow
- 11.3.4.2.4. By Sample
- 11.3.4.2.5. By Circulating Biomarker
- 11.3.4.2.6. By Application
- 11.3.4.2.7. By End User
- 11.3.5. Australia Liquid Biopsy Market Outlook
  - 11.3.5.1. Market Size & Forecast
    - 11.3.5.1.1. By Value
  - 11.3.5.2. Market Share & Forecast
    - 11.3.5.2.1. By Offering
    - 11.3.5.2.2. By Technology
    - 11.3.5.2.3. By Workflow
    - 11.3.5.2.4. By Sample
    - 11.3.5.2.5. By Circulating Biomarker
    - 11.3.5.2.6. By Application
    - 11.3.5.2.7. By End User
- 11.3.6. New Zealand Liquid Biopsy Market Outlook
  - 11.3.6.1. Market Size & Forecast
    - 11.3.6.1.1. By Value
  - 11.3.6.2. Market Share & Forecast
    - 11.3.6.2.1. By Offering
    - 11.3.6.2.2. By Technology
    - 11.3.6.2.3. By Workflow
    - 11.3.6.2.4. By Sample
    - 11.3.6.2.5. By Circulating Biomarker
    - 11.3.6.2.6. By Application
    - 11.3.6.2.7. By End User

## **12. SOUTH AMERICA LIQUID BIOPSY MARKET OUTLOOK**

- 12.1. Market Size & Forecast
  - 12.1.1. By Value
- 12.2. Market Share & Forecast
  - 12.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
  - 12.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
  - 12.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data

## Analysis & Management)

12.2.4. By Sample (Blood, Urine, Saliva, Others)

12.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)

12.2.6. By Application (Oncological v/s non-Oncological)

12.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)

12.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

12.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)

12.2.8. By Country

## 12.3. South America: Country Analysis

12.3.1. Brazil Liquid Biopsy Market Outlook

12.3.1.1. Market Size & Forecast

12.3.1.1.1. By Value

12.3.1.2. Market Share & Forecast

12.3.1.2.1. By Offering

12.3.1.2.2. By Technology

12.3.1.2.3. By Workflow

12.3.1.2.4. By Sample

12.3.1.2.5. By Circulating Biomarker

12.3.1.2.6. By Application

12.3.1.2.7. By End User

12.3.2. Argentina Liquid Biopsy Market Outlook

12.3.2.1. Market Size & Forecast

12.3.2.1.1. By Value

12.3.2.2. Market Share & Forecast

12.3.2.2.1. By Offering

12.3.2.2.2. By Technology

12.3.2.2.3. By Workflow

12.3.2.2.4. By Sample

12.3.2.2.5. By Circulating Biomarker

12.3.2.2.6. By Application

12.3.2.2.7. By End User

12.3.3. Colombia Liquid Biopsy Market Outlook

12.3.3.1. Market Size & Forecast

12.3.3.1.1. By Value

12.3.3.2. Market Share & Forecast



- 12.3.3.2.1. By Offering
- 12.3.3.2.2. By Technology
- 12.3.3.2.3. By Workflow
- 12.3.3.2.4. By Sample
- 12.3.3.2.5. By Circulating Biomarker
- 12.3.3.2.6. By Application
- 12.3.3.2.7. By End User

## **13. MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET OUTLOOK**

### 13.1. Market Size & Forecast

#### 13.1.1. By Value

### 13.2. Market Share & Forecast

#### 13.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)

#### 13.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)

#### 13.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

#### 13.2.4. By Sample (Blood, Urine, Saliva, Others)

#### 13.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Circulating Cell Free RNAs, Exosomes & Extracellular Vesicles, Others)

#### 13.2.6. By Application (Oncological v/s non-Oncological)

#### 13.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)

#### 13.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)

#### 13.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)

#### 13.2.8. By Country

### 13.3. MEA: Country Analysis

#### 13.3.1. Turkey Liquid Biopsy Market Outlook

##### 13.3.1.1. Market Size & Forecast

###### 13.3.1.1.1. By Value

##### 13.3.1.2. Market Share & Forecast

###### 13.3.1.2.1. By Offering

###### 13.3.1.2.2. By Technology

###### 13.3.1.2.3. By Workflow

###### 13.3.1.2.4. By Sample

###### 13.3.1.2.5. By Circulating Biomarker

- 13.3.1.2.6. By Application
- 13.3.1.2.7. By End User
- 13.3.2. Egypt Liquid Biopsy Market Outlook
  - 13.3.2.1. Market Size & Forecast
    - 13.3.2.1.1. By Value
  - 13.3.2.2. Market Share & Forecast
    - 13.3.2.2.1. By Offering
    - 13.3.2.2.2. By Technology
    - 13.3.2.2.3. By Workflow
    - 13.3.2.2.4. By Sample
    - 13.3.2.2.5. By Circulating Biomarker
    - 13.3.2.2.6. By Application
    - 13.3.2.2.7. By End User
- 13.3.3. Saudi Arabia Liquid Biopsy Market Outlook
  - 13.3.3.1. Market Size & Forecast
    - 13.3.3.1.1. By Value
  - 13.3.3.2. Market Share & Forecast
    - 13.3.3.2.1. By Offering
    - 13.3.3.2.2. By Technology
    - 13.3.3.2.3. By Workflow
    - 13.3.3.2.4. By Sample
    - 13.3.3.2.5. By Circulating Biomarker
    - 13.3.3.2.6. By Application
    - 13.3.3.2.7. By End User
- 13.3.4. South Africa Liquid Biopsy Market Outlook
  - 13.3.4.1. Market Size & Forecast
    - 13.3.4.1.1. By Value
  - 13.3.4.2. Market Share & Forecast
    - 13.3.4.2.1. By Offering
    - 13.3.4.2.2. By Technology
    - 13.3.4.2.3. By Workflow
    - 13.3.4.2.4. By Sample
    - 13.3.4.2.5. By Circulating Biomarker
    - 13.3.4.2.6. By Application
    - 13.3.4.2.7. By End User
- 13.3.5. UAE Liquid Biopsy Market Outlook
  - 13.3.5.1. Market Size & Forecast
    - 13.3.5.1.1. By Value
  - 13.3.5.2. Market Share & Forecast

- 13.3.5.2.1. By Offering
- 13.3.5.2.2. By Technology
- 13.3.5.2.3. By Workflow
- 13.3.5.2.4. By Sample
- 13.3.5.2.5. By Circulating Biomarker
- 13.3.5.2.6. By Application
- 13.3.5.2.7. By End User

## **14. MARKET DYNAMICS**

- 14.1. Drivers
- 14.2. Challenges

## **15. MARKET TRENDS & DEVELOPMENTS**

## **16. COMPETITIVE LANDSCAPE (INCLUSIVE OF SWOT ANALYSIS)**

- 16.1. F. Hoffmann-La Roche AG
- 16.2. Thermo Fisher Scientific, Inc.
- 16.3. PerkinElmer Inc.
- 16.4. LungLife AI, Inc.
- 16.5. Illumina, Inc.
- 16.6. QIAGEN NV
- 16.7. NeoGenomics Laboratories, Inc.
- 16.8. Myriad Genetics, Inc.
- 16.9. Biocept, Inc.
- 16.10. Bio-Rad Laboratories, Inc.
- 16.11. Guardant Health Inc.
- 16.12. Natera, Inc.
- 16.13. Sysmex Corporation
- 16.14. Abcodia Ltd.
- 16.15. Dxcover Limited

## **17. STRATEGIC RECOMMENDATIONS**

## **18. ABOUT US & DISCLAIMER**

## List Of Figures

### LIST OF FIGURES

Figure 1: Global Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 2: Global Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 3: Global Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F

Figure 4: Global Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 5: Global Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 6: Global Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F

Figure 7: Global Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 8: Global Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F

Figure 9: Global Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F

Figure 10: Global Liquid Biopsy Market Share, By End User, By Value, 2017-2027F

Figure 11: Global Liquid Biopsy Market Share, By Region, By Value, 2017-2027F

Figure 12: Global Liquid Biopsy Market Share, By Company, By Value, 2017-2027F

Figure 13: Global Liquid Biopsy Market Map, By Offering, Market Size (USD Million) & Growth Rate (%), 2021

Figure 14: Global Liquid Biopsy Market Map, By Technology, Market Size (USD Million) & Growth Rate (%), 2021

Figure 15: Global Liquid Biopsy Market Map, By Workflow, Market Size (USD Million) & Growth Rate (%), 2021

Figure 16: Global Liquid Biopsy Market Map, By Sample, Market Size (USD Million) & Growth Rate (%), 2021

Figure 17: Global Liquid Biopsy Market Map, By Circulating Biomarker, Market Size (USD Million) & Growth Rate (%), 2021

Figure 18: Global Liquid Biopsy Market Map, By Application, Market Size (USD Million) & Growth Rate (%), 2021

Figure 19: Global Liquid Biopsy Market Map, By End User, Market Size (USD Million) & Growth Rate (%), 2021

Figure 20: Global Liquid Biopsy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 21: North America Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 22: North America Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 23: North America Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F

Figure 24: North America Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 25: North America Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 26: North America Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F

Figure 27: North America Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 28: North America Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F

Figure 29: North America Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F

Figure 30: North America Liquid Biopsy Market Share, By End User, By Value, 2017-2027F

Figure 31: North America Liquid Biopsy Market Share, By Country, By Value, 2017-2027F

Figure 32: United States Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 33: United States Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 34: United States Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F

Figure 35: United States Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 36: United States Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 37: United States Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F

Figure 38: United States Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 39: United States Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F

Figure 40: United States Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F

Figure 41: United States Liquid Biopsy Market Share, By End User, By Value, 2017-2027F

Figure 42: Canada Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 43: Canada Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 44: Canada Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F

Figure 45: Canada Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 46: Canada Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 47: Canada Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F

Figure 48: Canada Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 49: Canada Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F

Figure 50: Canada Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F

Figure 51: Canada Liquid Biopsy Market Share, By End User, By Value, 2017-2027F

Figure 52: Mexico Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 53: Mexico Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 54: Mexico Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F

Figure 55: Mexico Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 56: Mexico Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 57: Mexico Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F

Figure 58: Mexico Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 59: Mexico Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F

Figure 60: Mexico Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F

Figure 61: Mexico Liquid Biopsy Market Share, By End User, By Value, 2017-2027F

Figure 62: Europe Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 63: Europe Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 64: Europe Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F

Figure 65: Europe Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 66: Europe Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 67: Europe Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F

Figure 68: Europe Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 69: Europe Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F

Figure 70: Europe Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F

Figure 71: Europe Liquid Biopsy Market Share, By End User, By Value, 2017-2027F

Figure 72: Europe Liquid Biopsy Market Share, By Country, By Value, 2017-2027F

Figure 73: Germany Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F

Figure 74: Germany Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F

Figure 75: Germany Liquid Biopsy Market Share, By Technology, By Value,  
2017-2027F

Figure 76: Germany Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F

Figure 77: Germany Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F

Figure 78: Germany Liquid Biopsy Market Share, By Circulating Biomarker, By Value,  
2017-2027F

Figure 79: Germany Liquid Biopsy Market Share, By Application, By Value, 2017-2027F

Figure 80: Germany Liquid Biopsy Market Share, By Application, By Oncological, By  
Value, 2017-2027F

Figure 81: Germany Liquid Biopsy Market Share, By Appl

## I would like to order

Product name: Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027

Product link: <https://marketpublishers.com/r/G510E2AE4EC5EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G510E2AE4EC5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_



Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970